I differ slightly with Bencro on buyout scenarios No question JV would be best for us and the tech. However, if a big pharma got concerned about being left out, they could go hostile. That would give them the software, patents and dosomitry. You would assume that Dr. Lilge and Dr. Jewett could be persuaded with the millions that would be exchanged to see the tech thru. I have worked for a company that has been bought and sold probably six times over the last thirty years. Most of the expertise transfers with the company especially when the employees just made a ton of money on stock options with the sale.Most takeovers are signed off on by the board of directors but there are times where an acquirer goes straight to the shareholders with a tender. Where I may differ with Bencro, is with all big pharma watching this with big interest, if they got consistent results with 9 patients with no life threatening side effects,no changes in bladder texture or function and efficacious results, I definitely see a possibility that one would try to go early. It would still be a lot cheaper, than waiting for the larger sample. I only suggest this because of the unusual nature of this situation. They all know it would be worth many billions and not one of them would turn down a chance to participate in what could be the ground floor of the future of tumor based oncology. This is all conjecture anyway, Bencro has pointed out that RW would likely stand aside and let a stronger company take the cancer side to the goal line. I stipulate because I could see RW retaining the therapeutic side and growing that division with marketing and targeted studies.